MedPath

GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

Not Applicable
Conditions
Healthy
Interventions
Other: 1,5 nmol/kg,GLP-1 sc injection
Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection
Other: Exendin-4 ;10 ug,sc injection
Other: saline
Registration Number
NCT01988545
Lead Sponsor
Zealand University Hospital
Brief Summary

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters

Detailed Description

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
8
Inclusion Criteria
  • healthy subjects
Exclusion Criteria
  • medical conditions

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
GLP-1 9-36amide1,5 nmol/kg,GLP-1 sc injection1,5 nmol/kg GLP-1 9-36amide, sc injection
GLP-11,5 nmol/kg GLP-1 9-36amide, sc injection1,5 nmol/kg,GLP-1 sc injection
GLP-1Exendin-4 ;10 ug,sc injection1,5 nmol/kg,GLP-1 sc injection
GLP-1 9-36amideExendin-4 ;10 ug,sc injection1,5 nmol/kg GLP-1 9-36amide, sc injection
Exendin-41,5 nmol/kg,GLP-1 sc injectionExendin-4 ;10 ug,sc injection
Exendin-41,5 nmol/kg GLP-1 9-36amide, sc injectionExendin-4 ;10 ug,sc injection
isotonic saline1,5 nmol/kg,GLP-1 sc injection2 ml of isotonic saline, sc injection
isotonic saline1,5 nmol/kg GLP-1 9-36amide, sc injection2 ml of isotonic saline, sc injection
isotonic salinesaline2 ml of isotonic saline, sc injection
Primary Outcome Measures
NameTimeMethod
blood flowwith in 120 minutes

blood flow change measured by ultra sound

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Køge Hospital

🇩🇰

Køge, State..., Denmark

© Copyright 2025. All Rights Reserved by MedPath